DeBattista C, Solvason HB, Breen JA, Schatzberg AF (2000). „Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression.”. J Clin Psychopharmacol. 20 (2): 274—275. PMID10770475. doi:10.1097/00004714-200004000-00029.
Zarate CA; Payne JL; Singh J; et al. (2004). „Pramipexole for bipolar II depression: a placebo-controlled proof of concept study”. Biol. Psychiatry. 56 (1): 54—60. PMID15219473. doi:10.1016/j.biopsych.2004.03.013.CS1 одржавање: Експлицитна употреба et al. (веза)
Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, Gemignani A, Battistini G, Bassi A, Abelli M, Cassano GB (2002). „Pramipexole in treatment-resistant depression: a 16-week naturalistic study.”. Bipolar Disord. 4 (5): 307—314. PMID12479663. doi:10.1034/j.1399-5618.2002.01171.x.
Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A, Cassano GB (2004). „Pramipexole in treatment-resistant depression: an extended follow-up.”. Depression and Anxiety. 20 (3): 131—138. PMID15549689. doi:10.1002/da.20038.
Holman AJ, Myers RR (2005). „A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.”. Arthritis Rheum. 52 (8): 2495—2505. PMID16052595. doi:10.1002/art.21191.
Schneider Claus; Mierau Joachim (1987). „Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analog of apomorphine”. Journal of Medicinal Chemistry. 30 (3): 494—8. PMID3820220. doi:10.1021/jm00386a009.
nih.gov
ncbi.nlm.nih.gov
DeBattista C, Solvason HB, Breen JA, Schatzberg AF (2000). „Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression.”. J Clin Psychopharmacol. 20 (2): 274—275. PMID10770475. doi:10.1097/00004714-200004000-00029.
Zarate CA; Payne JL; Singh J; et al. (2004). „Pramipexole for bipolar II depression: a placebo-controlled proof of concept study”. Biol. Psychiatry. 56 (1): 54—60. PMID15219473. doi:10.1016/j.biopsych.2004.03.013.CS1 одржавање: Експлицитна употреба et al. (веза)
Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, Gemignani A, Battistini G, Bassi A, Abelli M, Cassano GB (2002). „Pramipexole in treatment-resistant depression: a 16-week naturalistic study.”. Bipolar Disord. 4 (5): 307—314. PMID12479663. doi:10.1034/j.1399-5618.2002.01171.x.
Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A, Cassano GB (2004). „Pramipexole in treatment-resistant depression: an extended follow-up.”. Depression and Anxiety. 20 (3): 131—138. PMID15549689. doi:10.1002/da.20038.
Holman AJ, Myers RR (2005). „A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.”. Arthritis Rheum. 52 (8): 2495—2505. PMID16052595. doi:10.1002/art.21191.
Schneider Claus; Mierau Joachim (1987). „Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analog of apomorphine”. Journal of Medicinal Chemistry. 30 (3): 494—8. PMID3820220. doi:10.1021/jm00386a009.